DEA Targets Emerging Substance Threat with Bromazolam Scheduling

On March 18, 2026, the Drug Enforcement Administration (DEA) announced that it has temporarily placed bromazolam, a synthetic benzodiazepine, into Schedule I of the Controlled Substances Act due to increasing reports of trafficking and misuse.

According to the DEA, bromazolam is often used to manufacture counterfeit Xanax tablets and has become one of the most commonly identified benzodiazepines in illicit drug seizures. The agency determined the substance has a high potential for abuse and no current accepted medical use.

“The emergency scheduling of bromazolam is a decisive step to get ahead of a rapidly evolving threat. We will not wait for more lives to be put at risk,” said DEA Assistant Administrator Cheri Oz, Diversion Control Division. “This action closes dangerous gaps, disrupts access, and gives law enforcement and public health partners the tools they need to respond. Protecting our communities from emerging drugs is a top priority, and we will continue to act swiftly to stay ahead of those who seek to exploit them.”

The DEA also noted concerns about the health effects of bromazolam, including respiratory depression, impaired coordination, and altered mental state, as well as increasing co-use with opioids.

Read More